| The untapped potential of ascites in ovarian cancer research and treatment CE Ford, B Werner, NF Hacker, K Warton British journal of cancer 123 (1), 9-16, 2020 | 145 | 2020 |
| Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer B Werner, N Yuwono, J Duggan, D Liu, C David, S Srirangan, P Provan, ... Gynecologic Oncology 162 (3), 720-727, 2021 | 18 | 2021 |
| Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight B Werner, NL Yuwono, C Henry, K Gunther, RW Rapkins, CE Ford, ... PLoS One 14 (10), e0224338, 2019 | 17 | 2019 |
| Transcending Blood—Opportunities for Alternate Liquid Biopsies in Oncology B Werner, K Warton, CE Ford Cancers 14 (5), 1309, 2022 | 10 | 2022 |
| Circulating cell-free DNA undergoes significant decline in yield after prolonged storage time in both plasma and purified form NL Yuwono, MAA Boyd, CE Henry, B Werner, CE Ford, K Warton Clinical Chemistry and Laboratory Medicine (CCLM) 60 (8), 1287-1298, 2022 | 5 | 2022 |
| Endogenous Cell-free DNA in Fetal Bovine Serum Introduces Artifacts to in Vitro cell-free DNA Models B Werner, K Warton, CE Ford BioTechniques 73 (5), 219-226, 2022 | 2 | 2022 |
| Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response-a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial B Werner, KM Sjoquist, D Espinoza, S Yip, G Chang, MM Cummins, ... Translational Oncology 43, 101914, 2024 | | 2024 |
| Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer B Werner, E Powell, J Duggan, M Cortesi, YC Lee, V Arora, R Athavale, ... medRxiv, 2024.03. 09.24303840, 2024 | | 2024 |
| PR004/# 458 Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in a cohort of patients with advanced ovarian cancer B Werner, E Powell, J Duggan, YC Lee, R Athavale, M Dean, K Warton, ... International Journal of Gynecologic Cancer 33 (Suppl 4), 2023 | | 2023 |
| Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial. B Werner, KM Sjoquist, D Espinoza, S Yip, G Chang, MM Cummins, ... Journal of Clinical Oncology 41 (16_suppl), 5561-5561, 2023 | | 2023 |
